Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 15/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 4/20 | 0.52 |
| ▸ | IL1B | P01584 | 4/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836902 | 0.90 | CRBN (0.56) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL25582937 | 0.90 | CRBN (0.53) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL25575056 | 0.90 | CRBN (0.49) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL25034761 | 0.89 | CRBN (0.52) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL25582890 | 0.89 | CRBN (0.54) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL30135733 | 0.87 | CRBN (0.58) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL27099085 | 0.87 | CRBN (0.58) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL25036520 | 0.87 | CRBN (0.59) | CRBNIKZF3IKZF1CSNK1A1TNF | |
| SCHEMBL2249657 | 0.87 | CRBN (0.76) | CRBNIKZF3IKZF1TNFIL1B | |
| SCHEMBL27404250 | 0.86 | CRBN (0.66) | CRBNIKZF3IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | CRBN 77/4885IKZF3 2159/4885IKZF1 1718/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | CRBN 23/4885IKZF3 3499/4885IKZF1 3530/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | CRBN 77/4885IKZF3 2159/4885IKZF1 1718/4885 |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | GID4, RNF5, UBE3C | CRBN 105/4885IKZF3 2272/4885IKZF1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.